NO20011779L - Ureidopiperidinderivater som selektive humane NK3 reseptor antagonister - Google Patents

Ureidopiperidinderivater som selektive humane NK3 reseptor antagonister

Info

Publication number
NO20011779L
NO20011779L NO20011779A NO20011779A NO20011779L NO 20011779 L NO20011779 L NO 20011779L NO 20011779 A NO20011779 A NO 20011779A NO 20011779 A NO20011779 A NO 20011779A NO 20011779 L NO20011779 L NO 20011779L
Authority
NO
Norway
Prior art keywords
ureidopiperidine
derivatives
receptor antagonists
selective human
selective
Prior art date
Application number
NO20011779A
Other languages
English (en)
Norwegian (no)
Other versions
NO20011779D0 (no
Inventor
Alain Aulombard
Xavier Emonds-Alt
Vincenzo Proietto
Didier Van Broeck
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NO20011779D0 publication Critical patent/NO20011779D0/no
Publication of NO20011779L publication Critical patent/NO20011779L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20011779A 1998-10-09 2001-04-06 Ureidopiperidinderivater som selektive humane NK3 reseptor antagonister NO20011779L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9812859A FR2784377B3 (fr) 1998-10-09 1998-10-09 Nouveaux composes derives d'ureidopiperidine, antagonistes selectifs des recepteurs nk3 humains, procede pour leur obtention et compositions pharmaceutiques les contenant
PCT/FR1999/002355 WO2000021931A1 (fr) 1998-10-09 1999-10-04 Derives d'ureidopiperidine comme antagonistes selectifs des recepteurs nk3 humains

Publications (2)

Publication Number Publication Date
NO20011779D0 NO20011779D0 (no) 2001-04-06
NO20011779L true NO20011779L (no) 2001-06-07

Family

ID=9531536

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011779A NO20011779L (no) 1998-10-09 2001-04-06 Ureidopiperidinderivater som selektive humane NK3 reseptor antagonister

Country Status (25)

Country Link
US (1) US6465489B1 (zh)
EP (1) EP1119552A1 (zh)
JP (1) JP2002527423A (zh)
KR (1) KR20010085903A (zh)
CN (1) CN1133622C (zh)
AR (1) AR029148A1 (zh)
AU (1) AU751592B2 (zh)
BR (1) BR9914397A (zh)
CA (1) CA2346729A1 (zh)
CO (1) CO5180555A1 (zh)
DZ (1) DZ2905A1 (zh)
EA (1) EA003613B1 (zh)
EE (1) EE200100214A (zh)
FR (1) FR2784377B3 (zh)
HU (1) HUP0201709A3 (zh)
IL (1) IL142362A0 (zh)
IS (1) IS5897A (zh)
NO (1) NO20011779L (zh)
NZ (1) NZ510779A (zh)
PL (1) PL347910A1 (zh)
SK (1) SK4642001A3 (zh)
TR (1) TR200101030T2 (zh)
TW (1) TW539669B (zh)
WO (1) WO2000021931A1 (zh)
YU (1) YU26001A (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068604A2 (en) 2000-03-14 2001-09-20 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
US20060128752A1 (en) * 2002-07-03 2006-06-15 Giuseppe Alvaro Chemical compounds
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
US9554659B2 (en) 2012-10-22 2017-01-31 Uwm Research Foundation, Inc. Infant sleep pod
EP3881843A4 (en) * 2018-11-15 2022-08-03 Kyushu University, National University Corporation PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICAL COMPOSITION FOR IL-31 MEDIATED DISEASE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2688219B1 (fr) * 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2719311B1 (fr) 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2738819B1 (fr) 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
AU4176997A (en) 1996-09-16 1998-04-02 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines

Also Published As

Publication number Publication date
NZ510779A (en) 2003-07-25
CO5180555A1 (es) 2002-07-30
TW539669B (en) 2003-07-01
TR200101030T2 (tr) 2001-08-21
IS5897A (is) 2001-03-16
EE200100214A (et) 2002-08-15
EA200100299A1 (ru) 2001-10-22
SK4642001A3 (en) 2001-09-11
NO20011779D0 (no) 2001-04-06
DZ2905A1 (fr) 2004-03-01
JP2002527423A (ja) 2002-08-27
CN1133622C (zh) 2004-01-07
IL142362A0 (en) 2002-03-10
AU751592B2 (en) 2002-08-22
KR20010085903A (ko) 2001-09-07
AU5988799A (en) 2000-05-01
AR029148A1 (es) 2003-06-18
FR2784377B3 (fr) 2000-11-17
EP1119552A1 (fr) 2001-08-01
CA2346729A1 (en) 2000-04-20
US6465489B1 (en) 2002-10-15
YU26001A (sh) 2003-04-30
HUP0201709A2 (en) 2002-09-28
EA003613B1 (ru) 2003-06-26
BR9914397A (pt) 2001-06-26
CN1329594A (zh) 2002-01-02
FR2784377A1 (fr) 2000-04-14
PL347910A1 (en) 2002-04-22
HUP0201709A3 (en) 2003-03-28
WO2000021931A1 (fr) 2000-04-20

Similar Documents

Publication Publication Date Title
DE60026169D1 (de) Selektive neurokinin-antagonisten
DK0901470T3 (da) Indolderivater egnede som endothelinreceptorantagonister
NO965036D0 (no) Kinolinderivater som techykinin NK3 reseptor-antagonister
NO20012948D0 (no) Hydroksydifenylureasulfonamider som IL-8 reseptor antagonister
IS5706A (is) Adenosín A3 viðtakastillar
ATE312819T1 (de) 4,4-biarylpiperidinederivate mit opioid-receptor- wirkung
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
CY2011002I1 (el) N-πυρραζολικοι αγωνιστες του α2α υποδοχεα
DE69734833D1 (de) Vitronektin rezeptor antagonisten
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
DE69921351D1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
ID24726A (id) Antagonis-antagonis reseptor trombin
DK1027342T3 (da) Cyclopentenderivater som motilinreceptorantagonister
NO20013997L (no) Reseptoranalyse
ID24162A (id) Antagonis-antagonis reseptor vitronektin
DE69933135D1 (de) Benzimidazolderivate mit vitronectinrezeptor-antagonistischer wirkung
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
BR9709982A (pt) Derivados de indolina úteis como antagonistas do receptor 5-ht-2c
ID28811A (id) Antagonis reseptor vitronektin
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
NO20011779D0 (no) Ureidopiperidinderivater som selektive humane NK3 reseptor antagonister
NO985972D0 (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
NO20021295D0 (no) Nikotinsyreacetylcholin-reseptor
NO20002575D0 (no) Substituerte oksimer som neurokininantagonister